Miraca to Promote MDxHealth's Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – MDxHealth today announced a deal with Miraca Life Sciences to promote MDxHealth's ConfirmMDx Prostate Cancer test.

"Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay, which delivers new molecular insights on a patient's risk for undetected cancer, thereby enabling our clients make more informed decisions about the need for a repeat prostate biopsy," Miraca President and CEO Frank Basile said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.